Qin Zeng

Dr. Qin Zeng


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XMXIE MZ
XIE MZ
TGTaojun Gong
Taojun Gong
YWYitian Wang
Yitian Wang
ZLZhuangzhuang Li
Zhuangzhuang Li
MLMinxun Lu
Minxun Lu
YZYong Zhou
Yong Zhou
Bone tumors, particularly osteosarcoma, are prevalent among children and adolescents. This ailment has emerged as the second most frequent cause of cancer-related mortality in adolescents. Conventional treatment methods comprise extensive surgical resection, radiotherapy, and chemotherapy. Consequently, the management of bone tumors and bone regeneration poses significant clinical challenges. Photothermal tumor therapy has attracted considerable attention owing to its minimal invasiveness and high selectivity. However, key challenges have limited its widespread clinical use. Enhancing the tumor specificity of photosensitizers through targeting or localized activation holds potential for better outcomes with fewer adverse effects. Combinations with chemotherapies or immunotherapies also present avenues for improvement. In this review, we provide an overview of the most recent strategies aimed at overcoming the limitations of photothermal therapy (PTT), along with current research directions in the context of bone tumors, including (1) target strategies, (2) photothermal therapy combined with multiple therapies (immunotherapies, chemotherapies, and chemodynamic therapies, magnetic, and photodynamic therapies), and (3) bifunctional scaffolds for photothermal therapy and bone regeneration. We delve into the pros and cons of these combination methods and explore current research focal points. Lastly, we address the challenges and prospects of photothermal combination therapy.

21 April 2023 in Acta Biomaterialia
Verified
Journal Article
Closed access
RWRuiqi Wang
Ruiqi Wang
YHYuchen Hua
Yuchen Hua
HWHongfeng Wu
Hongfeng Wu
JWJingyu Wang
Jingyu Wang
YXYou-Cai Xiao
You-Cai Xiao
XZXingdong Zhang
Xingdong Zhang

1 November 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
YHYuchen Hua
Yuchen Hua
WWWu Wu
Wu Wu
HWHongfeng Wu
Hongfeng Wu
CSCheng Su
Cheng Su
XLXiangfeng Li
Xiangfeng Li
XZXingdong Zhang
Xingdong Zhang

11 September 2024 in Advanced Science
Verified
Journal Article
Open access
ZLZhongjie Liu
Zhongjie Liu
SLShu Li
Shu Li
YXYang Xiao
Yang Xiao
XLXiaoyang Liu
Xiaoyang Liu
BZBin Zhang
Bin Zhang
XZXingdong Zhang
Xingdong Zhang
The effectiveness of Toll‐like 9 agonists (CpG) as an adjuvant for tumor immunotherapy is restricted due to their insufficient ability to activate anti‐tumor immunity. To address that, the common nutrient metal ions are explored (Mn2+, Cu2+, Ca2+, Mg2+, Zn2+, Fe3+, and Al3+), identifying Mn2+ as a key enhancer of CpG to mediate immune activation by augmenting the STING‐NF‐κB pathway. Mn2+ and CpG are then self‐assembled with epigallocatechin gallate (EGCG) into a nanoadjuvant MPN/CpG. Local delivery of MPN/CpG effectively inhibits tumor growth in a B16 melanoma‐bearing mouse model, reshaping the tumor microenvironment (TME) by repolarizing M2‐type tumor‐associated macrophages (TAMs) to an M1‐type and boosting intra‐tumoral infiltration of CD8+/CD4+ T lymphocytes and DCs. Furthermore, compared to free CpG, MPN/CpG exhibits heightened accumulation in lymph nodes, enhancing CpG uptake and DC activation, consequently inducing significant antigen‐specific cytotoxic CD8+ T cell immune response and humoral immunity. In a prophylactic tumor‐bearing mouse model, MPN/CpG vaccination with OVA antigen significantly delays B16‐OVA melanoma growth and extends mouse survival. These findings underscore the potential of MPN/CpG as a multifunctional adjuvant platform to drive powerful innate and adaptive immunity and regulate TME against tumors.

23 October 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
XLXiaoyang Liu
Xiaoyang Liu
ZZZongke Zhou
Zongke Zhou
WZWei-Nan Zeng
Wei-Nan Zeng
QZQin Zeng
Qin Zeng
XZXingdong Zhang
Xingdong Zhang
Osteoimmunology is a concept involving molecular and cellular crosstalk between the skeletal and immune systems. Toll-like receptors (TLRs) are widely expressed both on mesenchymal stromal cells (MSCs), the hematopoietic cells, and immune cells in the osteogenic microenvironment for bone development or repair. TLRs can sense both exogenous pathogen-associated molecular patterns (PAMPs) derived from microorganisms, and damage-associated molecular patterns (DAMPs) derived from normal cells subjected to injury, inflammation, or cell apoptosis under physiological or pathological conditions. Emerging studies reported that TLR signaling plays an important role in bone remodeling by directly impacting MSC osteogenic differentiation or osteoimmunology. However, how to regulate TLR signaling is critical and remains to be elucidated to promote the osteogenic differentiation of MSCs and new bone formation for bone tissue repair. This review outlines distinct TLR variants on MSCs from various tissues, detailing the impact of TLR pathway activation or inhibition on MSC osteogenic differentiation. It also elucidates TLR pathways’ interplay with osteoclasts, immune cells, and extracellular vesicles (EVs) derived from MSCs. Furthermore, we explore biomaterial-based activation to guide MSCs’ osteogenic differentiation. Therefore, understanding TLRs’ role in this context has significant implications for advancing bone regeneration and repair strategies.

10 January 2025 in Chemical Engineering Journal
Verified
Journal Article
Closed access
QZQin Zeng
Qin Zeng
YZYing Zhang
Ying Zhang
JZJudun Zheng
Judun Zheng
JLJingyan Lin
Jingyan Lin
NLNing Li
Ning Li
YLYuhui Liao
Yuhui Liao